NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. today announced the pricing of its initial public offering of 6,250,000 shares of common stock at $12.00 per share, before underwriting discounts and commissions. Kadmon has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price. Kadmon’s common stock is expected to begin trading on July 27, 2016, on the New York Stock Exchange under the symbol “KDMN”. The offering is expected to close on August 1, 2016, subject to customary closing conditions.

Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager and H.C. Wainwright & Co., LLC is acting as manager for the offering.

About Kadmon

Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. Kadmon is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases.